Dosing-time, feeding, and sex-dependent variations of everolimus pharmacokinetics in mice.
Dilek Öztürk CivelekNarin Ozturk SeyhanYasemin Kubra AkyelIsil GaziogluZeliha Pala KaraMehmet N OrmanAlper OkyarPublished in: Fundamental & clinical pharmacology (2024)
Our findings imply that the pharmacokinetics of everolimus in mice may differ according to dosing time, sex, and feeding. Greater tissue distribution of everolimus at ZT1 may be associated with the worst tolerated time of everolimus. Our research suggests that oral chronomodulated everolimus therapy may be more effective and safer for cancer patients.